Session 1: Biological, Experimental and Methodological Challenges Associated with the Study of Drug Metabolizing Enzymes

Chairs: Christopher Gibson, Merck & Co., Inc., West Point, Pennsylvania, USA and Adrian Fretland, Repare Therapeutics, Cambridge, Massachusetts, USA

Methods to Understand the Role of Gut and Liver CYP and UGT in Human PK Variability and DDI 
 Yingying Guo, Eli Lilly and Company, Indianapolis, Indiana, USA 

Can we accurately measure free fraction of highly bound compounds for use in DDI risk assessment in the clinic?: IQ TALG Plasma Protein Binding Working Group  
 Faraz Kazmi, Janssen Research & Development, Spring House, Pennsylvania, USA

Derivation of Unbound Ki for Metabolic Enzymes: What have we learnt?
Renu Singh, GSK, Phoenixville, Pennsylvania, USA

Microphysiological Model to Investigate Ochratoxin A Nephrotoxicity 
 Edward Kelly, University of Washington, Seattle, Washington, USA

Kinetics and in vitro Challenges with AO
 Kanika Choughule, Merck & Co., Inc., Boston, Massachusetts, USA

Intestine Explant Barrier Chip: A Medium Throughput Microfluidic System to Study Drug Permeability and Host-microbe Interactions in ex vivo Intestinal Tissue
Joanne Donkers, TNO, Zeist, The Netherlands

Panel Discussion with All Speakers